TearLab Corporation

TearLab Corporation is an ophthalmic device company developing and commercializing novel, lab-on-a-chip technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.

Conventional tear testing systems are not suitable for clinical use due to their high cost and complexity, the need for large sample volumes, and the length of time required for testing. The TearLab^TM System requires nanoliters of tears for testing, potentially reducing collection time and simplifying the tear collection process.

TearLab Corporation headquartered in San Diego, California, is commercializing a proprietary in vitro diagnostic tear testing platform, The TearLab^TM Osmolarity System, which is capable of accurately and rapidly measuring biomarkers in tears at the point-of-care.

TearLab Corporation's common shares trade on the NASDAQ Global Market under the symbol TEAR and on the Toronto Stock Exchange under the symbol 'TLB'.